BR112016025132A2 - compostos polifluorados agindo como inibidores de tirosina quinase de bruton - Google Patents
compostos polifluorados agindo como inibidores de tirosina quinase de brutonInfo
- Publication number
- BR112016025132A2 BR112016025132A2 BR112016025132A BR112016025132A BR112016025132A2 BR 112016025132 A2 BR112016025132 A2 BR 112016025132A2 BR 112016025132 A BR112016025132 A BR 112016025132A BR 112016025132 A BR112016025132 A BR 112016025132A BR 112016025132 A2 BR112016025132 A2 BR 112016025132A2
- Authority
- BR
- Brazil
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- compounds acting
- bruton tyrosine
- polyfluorinated compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/38—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reaction of ammonia or amines with sulfonic acids, or with esters, anhydrides, or halides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
- C07C43/29—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
- C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Abstract
fornecidos são os novos compostos de pirazolopirimidina substituídos por polifluoro ou sais representados por fórmula (i) a (ix), um método de preparação destes e um método para usar os ditos compostos e uma preparação destes para tratar e inibir doenças ou transtornos autoimunes, doenças ou transtornos heteroimunes, doenças inflamatórias e cânceres ou transtornos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410175783.7A CN105017256A (zh) | 2014-04-29 | 2014-04-29 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
PCT/CN2015/000290 WO2015165279A1 (zh) | 2014-04-29 | 2015-04-27 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016025132A2 true BR112016025132A2 (pt) | 2017-08-15 |
Family
ID=54358137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016025132A BR112016025132A2 (pt) | 2014-04-29 | 2015-04-27 | compostos polifluorados agindo como inibidores de tirosina quinase de bruton |
Country Status (14)
Country | Link |
---|---|
US (3) | US9532990B2 (pt) |
EP (1) | EP3138842B1 (pt) |
JP (2) | JP6670756B2 (pt) |
KR (2) | KR20160144378A (pt) |
CN (3) | CN105017256A (pt) |
AU (1) | AU2015252654C1 (pt) |
BR (1) | BR112016025132A2 (pt) |
CA (1) | CA2947338C (pt) |
EA (2) | EA037227B1 (pt) |
ES (1) | ES2857251T3 (pt) |
HK (1) | HK1256857A1 (pt) |
IL (1) | IL248546B (pt) |
MX (2) | MX2016014248A (pt) |
WO (1) | WO2015165279A1 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014291161B2 (en) | 2013-07-18 | 2018-04-26 | Taiho Pharmaceutical Co., Ltd. | Antitumor drug for intermittent administration of FGFR inhibitor |
WO2015008844A1 (ja) | 2013-07-18 | 2015-01-22 | 大鵬薬品工業株式会社 | Fgfr阻害剤耐性癌の治療薬 |
CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
WO2016079693A1 (en) * | 2014-11-19 | 2016-05-26 | Sun Pharmaceutical Industries Limited | A process for the preparation of ibrutinib |
EP3257855B1 (en) * | 2015-02-12 | 2020-04-22 | Shanghai Dude Medical Science and Technology Co., Ltd. | Method for preparing ibrutinib |
US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
CN106146511A (zh) * | 2015-04-03 | 2016-11-23 | 安润医药科技(苏州)有限公司 | 吡唑并嘧啶衍生物、制备方法、药物组合物及用途 |
CN106146512B (zh) * | 2015-04-09 | 2018-07-17 | 北京睿创康泰医药研究院有限公司 | 依鲁替尼的制备方法 |
WO2016168704A1 (en) | 2015-04-16 | 2016-10-20 | Icahn School Of Medicine At Mount Sinai | Ksr antagonists |
KR20220110859A (ko) | 2016-03-04 | 2022-08-09 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
JP6959252B2 (ja) * | 2016-03-24 | 2021-11-02 | ミッション セラピューティクス リミティド | Dub阻害剤としての1−シアノピロリジン誘導体 |
CN106146518A (zh) * | 2016-06-30 | 2016-11-23 | 苏州爱玛特生物科技有限公司 | 一种布鲁顿酪氨酸激酶抑制剂中间体及其制备方法 |
WO2018002958A1 (en) | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
EP3543239A1 (en) * | 2016-11-15 | 2019-09-25 | Hangzhou Hertz Pharmaceutical Co., Ltd. | Selective bruton's tyrosine kinase inhibitor and use thereof |
JP2020511462A (ja) | 2016-12-03 | 2020-04-16 | ジュノー セラピューティクス インコーポレイテッド | キナーゼ阻害剤との組み合わせで治療用t細胞を使用するための方法および組成物 |
CN106831788B (zh) * | 2017-01-22 | 2020-10-30 | 鲁南制药集团股份有限公司 | 伊布替尼精制方法 |
AU2018237123B2 (en) * | 2017-03-22 | 2022-08-04 | Xibin Liao | Bruton's tyrosine kinase inhibitors |
CN107501270B (zh) * | 2017-09-01 | 2019-06-28 | 宏腾建设集团有限公司 | 一种含有磺酰吖丙啶结构的化合物、药物组合物以及其应用 |
TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
CN109970740A (zh) * | 2017-12-27 | 2019-07-05 | 广东众生药业股份有限公司 | 4-氨基-嘧啶并氮杂环衍生物及其制备方法和用途 |
US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
WO2020096042A1 (ja) * | 2018-11-09 | 2020-05-14 | 大鵬薬品工業株式会社 | ジメトキシベンゼン化合物の製造方法 |
CN111171035B (zh) * | 2018-11-13 | 2021-03-30 | 山东大学 | 4-苯氧基苯基吡唑并嘧啶酰胺衍生物的制备方法和应用 |
CN111454268B (zh) * | 2019-01-18 | 2023-09-08 | 明慧医药(上海)有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
US20220386606A1 (en) | 2019-03-15 | 2022-12-08 | Bayer Aktiengesellschaft | Specifically substituted 3-phenyl-5-spirocyclopentyl-3-pyrrolin-2-ones and their use as herbicides |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP3964512A4 (en) * | 2019-06-27 | 2022-08-10 | Hangzhou Healzen Therapeutics Co., Ltd. | CASEINKINASE-1-EPSILON INHIBITOR, PHARMACEUTICAL COMPOSITION AND ITS USE |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
LT4036095T (lt) | 2019-09-26 | 2024-03-25 | Jumbo Drug Bank Co., Ltd. | 4-fluor-1h-pirazolo[3,4-c]piridino dariniai kaip selektyvūs brutono tirozino kinazės (btk) inhibitoriai, skirti gydyti b ląstelių limfomą ir autoimunines ligas |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP3865535A1 (en) | 2020-02-11 | 2021-08-18 | Bosti Trading Ltd. | New method of synthesis of chitosan derivatives and uses thereof |
TW202144465A (zh) | 2020-02-11 | 2021-12-01 | 瑞士商諾和席卓股份有限公司 | 合成聚葡萄胺糖衍生物之新方法及其用途 |
AU2020436612A1 (en) * | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
CN116075513A (zh) | 2020-06-08 | 2023-05-05 | 哈利亚治疗公司 | Nek7激酶的抑制剂 |
CN113943294A (zh) * | 2020-07-15 | 2022-01-18 | 成都海博为药业有限公司 | 一种作为btk抑制剂的化合物及其制备方法与用途 |
WO2022081512A1 (en) * | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
CN112574046A (zh) * | 2020-12-17 | 2021-03-30 | 深圳市华先医药科技有限公司 | 一种制备(1r,3s)-3-氨基环戊醇盐酸盐的方法 |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
CN117042769A (zh) * | 2021-02-03 | 2023-11-10 | 冰洲石生物科技公司 | 作为布鲁顿酪氨酸激酶(btk)降解剂的取代的吡咯并嘧啶和吡唑并嘧啶 |
WO2023012333A2 (en) | 2021-08-06 | 2023-02-09 | Novochizol Sa | Preparation of composite gels, polymer scaffolds, aggregates and films comprising soluble cross-linked chitosan & uses thereof |
AR126678A1 (es) | 2021-08-06 | 2023-11-01 | Novochizol Sa | Composiciones para el cuidado de las plantas y usos de las mismas |
CN114605418B (zh) * | 2022-03-15 | 2023-09-05 | 广东医科大学附属医院 | 一类具有抗肿瘤活性的依鲁替尼丙烯酰胺类衍生物及其合成方法与应用 |
CN117430610A (zh) * | 2023-10-11 | 2024-01-23 | 宁夏医科大学 | 一种氘代稠合杂环化合物及其制备方法和应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
KR101315610B1 (ko) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
EP1921149A1 (en) | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
CA2874756C (en) | 2007-03-28 | 2018-05-29 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
ES2660418T3 (es) * | 2008-07-16 | 2018-03-22 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
CN102115476A (zh) * | 2011-03-23 | 2011-07-06 | 常州大学 | 一种2H-吡唑并[3,4-d]嘧啶衍生物及合成方法 |
US9376438B2 (en) * | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
BR112013028846B1 (pt) * | 2011-05-17 | 2021-12-07 | Principia Biopharma Inc | Composto ou sal farmaceuticamente aceitável do mesmo, respectivos usos, processo de preparação, intermediários e composição farmacêutica |
KR20140048968A (ko) * | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
CN104487441B (zh) * | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
ES2682043T3 (es) * | 2012-07-30 | 2018-09-18 | Concert Pharmaceuticals Inc. | Ibrutinib deuterado |
CN104540455A (zh) * | 2012-07-31 | 2015-04-22 | 安全电线控股有限责任公司 | 深度可控的贾姆什迪针 |
WO2014022569A1 (en) * | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
US9266895B2 (en) * | 2012-09-10 | 2016-02-23 | Principia Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors |
US9479134B2 (en) * | 2013-03-04 | 2016-10-25 | Texas Instruments Incorporated | Position detecting system |
WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
CN105263496A (zh) | 2013-04-08 | 2016-01-20 | 药品循环有限责任公司 | 依鲁替尼联合疗法 |
CA2908776C (en) | 2013-04-08 | 2021-08-10 | Bayer Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
CN105408334B (zh) * | 2013-05-21 | 2017-10-10 | 江苏迈度药物研发有限公司 | 作为激酶抑制剂的取代的吡唑并嘧啶类化合物 |
CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
-
2014
- 2014-04-29 CN CN201410175783.7A patent/CN105017256A/zh active Pending
-
2015
- 2015-04-27 EA EA201892740A patent/EA037227B1/ru unknown
- 2015-04-27 EP EP15785217.9A patent/EP3138842B1/en active Active
- 2015-04-27 WO PCT/CN2015/000290 patent/WO2015165279A1/zh active Application Filing
- 2015-04-27 MX MX2016014248A patent/MX2016014248A/es unknown
- 2015-04-27 MX MX2021013118A patent/MX2021013118A/es unknown
- 2015-04-27 EA EA201692176A patent/EA032100B1/ru unknown
- 2015-04-27 KR KR1020167028059A patent/KR20160144378A/ko active Application Filing
- 2015-04-27 AU AU2015252654A patent/AU2015252654C1/en active Active
- 2015-04-27 CN CN201580010345.8A patent/CN106061976B/zh active Active
- 2015-04-27 ES ES15785217T patent/ES2857251T3/es active Active
- 2015-04-27 KR KR1020237032203A patent/KR20230137499A/ko active IP Right Grant
- 2015-04-27 CA CA2947338A patent/CA2947338C/en active Active
- 2015-04-27 BR BR112016025132A patent/BR112016025132A2/pt not_active Application Discontinuation
- 2015-04-27 CN CN201810371229.4A patent/CN108295073B/zh active Active
- 2015-04-27 JP JP2016565402A patent/JP6670756B2/ja active Active
-
2016
- 2016-03-18 US US15/075,033 patent/US9532990B2/en active Active
- 2016-10-27 IL IL248546A patent/IL248546B/en active IP Right Grant
- 2016-11-18 US US15/356,014 patent/US9861636B2/en active Active
-
2017
- 2017-11-22 US US15/820,614 patent/US10300066B2/en active Active
-
2018
- 2018-12-12 HK HK18115945.4A patent/HK1256857A1/zh unknown
-
2019
- 2019-12-05 JP JP2019220363A patent/JP7005582B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016025132A2 (pt) | compostos polifluorados agindo como inibidores de tirosina quinase de bruton | |
BR112018069612A2 (pt) | compostos de pirroltriazina como inibidores de tam | |
CL2017000786A1 (es) | Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos. | |
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
EA201991198A1 (ru) | АМИНОТИАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit | |
EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
BR112016025427A2 (pt) | processos de preparação de um inibidor de jak1 e formas do mesmo | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
EA201692338A1 (ru) | Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы | |
TR201906366T4 (tr) | Polisiklik-karbamoilpiridon bileşiklerinin sentezi. | |
EA201692219A1 (ru) | Способы получения противовирусных соединений | |
EA201591889A1 (ru) | 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd | |
UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
EA201692425A1 (ru) | Модифицированные биополимеры и способы их получения и использования | |
EA201790418A1 (ru) | Пиримидиниловые ингибиторы тирозинкиназы | |
UY37015A (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
EA201790982A1 (ru) | Синтез копанлисиба и его дигидрохлорида | |
EA201790570A1 (ru) | Модуляторы р2х7 | |
EA201790207A8 (ru) | Новые замещенные пиримидиновые соединения | |
CO2017001389A2 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
BR112018011525A2 (pt) | inibidores da tirosina quinase de bruton e métodos de seu uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |